Resources and Tools

A recent study published in Drug and Alcohol Dependence found evidence for racial/ethnic disparities in buprenorphine distribution across the United States.

Transgender people and communities, including nonbinary people, have specific needs within harm reduction programs.

This report analyzes the issues and trends underlying the syndemics of HIV, SUD, and viral hepatitis in West Virginia.

This document provides a quick overview of the federal discretionary funding programs that support essential aspects of the nation’s HIV response.

In recent years, the gap in the rate of opioid overdoses among Black and white Americans has narrowed significantly, with increases in Black mortality driven in part by the addition of synthetic opioids to other drugs.

Achieving the goals of the Ending the HIV Epidemic (EHE) Initiative depends on doing more to strengthen communities, reduce the harm associated with drug use, and prevent disease transmission.

This webinar companion guide provides information for the January 2021 Strengthening Systems of Care: Supporting People with HIV and Opioid Use Disorder following Incarceration webinar.

Opioid agonist treatment (OAT) is the provision of medications (methadone and buprenorphine) that activate the opioid receptors to prevent withdrawal and reduce cravings for opioids.

This publication, part of SAMHSA's Evidence Based Resource Guide series, addresses the co-occurrence of HIV and mental illness and/or SUD.